A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)